Skip to main content
. Author manuscript; available in PMC: 2020 May 1.
Published in final edited form as: Neuropharmacology. 2019 Feb 20;149:161–168. doi: 10.1016/j.neuropharm.2019.02.024

Figure 3: gp120 activates CXCR4 to stimulate microglia and increase tonic inhibition.

Figure 3:

(A) The CXCR4 antagonist, AMD3100 (1 µM), inhibits gp120-induced (600 pM) increases in bicuculline-sensitive holding current normalized to whole-cell capacitance (two-way ANOVA; F(1,28)=6.00, p=0.02). (B) Representative images showing microglia labeled by Ox-42 antibody (yellow) were depleted relative to MAP2 immunoreactive neurons (red) 24 h after treatment with LME (25 mM for 1 h) compared to DMEM wash controls. (C) Removal of microglia with LME blocks gp120-induced increases in tonic current (two-way ANOVA; F(1,21)=7.63, p=0.01) compared to DMEM wash. Data are expressed as individual data points with mean ± SEM. Two-way ANOVAs were followed by Tukey’s post hoc test, **p<0.01 compared to untreated or DMEM control. ##p<0.01 compared to gp120 alone (untreated or DMEM).